CHIBA, Japan - August 21, 2025 - Eczema affects 31 million Americans, creating daily challenges that extend far beyond visible symptoms. ATOPIYO LLC, developer of Japan's largest eczema patient app, today announced the launch of "Tweet Piyo," a new short text-only posting feature that allows users to share thoughts, questions, and daily experiences without requiring photos. Additionally, the app introduces a blur function that gives users control over viewing sensitive images.
Background: Meeting User Needs
Until now, ATOPIYO has been widely used for sharing and recording eczema-related photos to foster empathy and information exchange among patients. However, many users expressed a desire to also post quick notes such as “I just want to ask in words” or “I want to share my daily worries and findings without an image.” The new text posting feature "Tweet Piyo" addresses this demand, making communication easier and more inclusive.
For image posts, a new function allows users to blur photos posted by others, such as severe cases, giving them control over what they view.
How It Works
Text Posting – Tap the pencil icon at the bottom of the app to write and share a text-only post.
Blur – Tap the eye icon in the lower right corner to toggle blurred or unblurred display of images.
About ATOPIYO
ATOPIYO is Japan's first anonymous image-sharing app specifically designed for eczema patients. Developed by former eczema patient Ryotaro Ako, the app enables users to anonymously record and share eczema-specific skin symptoms, itching experiences, and skincare routines to support early recovery.
Since launch, ATOPIYO has grown into Japan’s largest eczema patient platform, with over 30,000 downloads and 67,000 uploaded images as of August 2025. It has won 12 national awards, including Japan’s National Public Health Award. The app has also launched in the United States in June 2025.
ATOPIYO currently collaborates with 7 university hospitals and research institutions for big data analysis and pharmaceutical partnerships for disease awareness. Research utilizing ATOPIYO data was published in the prestigious international medical journal "Allergy" in May 2025, demonstrating its academic impact.
AppStore: https://apps.apple.com/app/id6475762535
GooglePlay: https://play.google.com/store/apps/details?id=com.atopiyo.atopiyous
Future Outlook
ATOPIYO will continue partnering with pharmaceutical companies and medical institutions to advance eczema research, product development, and disease awareness through digital innovation. The addition of text posting is the first of many planned feature expansions aimed at creating a more comprehensive and supportive platform for eczema patients.
"With 31 million Americans living with eczema, our mission goes beyond symptom tracking. The text posting feature reflects our commitment to meeting the evolving needs of our community." — Ryotaro Ako, Founder of ATOPIYO
Founder's Profile
Ryotaro Ako, a former eczema patient, is a programmer, holds a master’s degree in engineering, and is a Certified Public Accountant. Having experienced three allergic conditions—eczema, asthma, and rhinitis—he engaged in volunteer work with patient associations. He developed ATOPIYO himself, drawing on feedback from eczema patients, insights from his wife Akiko Ako, a licensed pharmacist, and technical guidance from software engineers.
Major Awards
10th Health and Longevity Extension! Award – National Government Public Health Award
InnoVation 2020 Generation Award – National Government Innovation Award
Japan Healthcare Business Contest 2020 – National Government Excellence & Special Awards
Media Contact
Company Name: Atopiyo LLC
Contact Person: Ryotaro Ako
Email: Send Email
City: Ichikawa
State: Chiba
Country: Japan
Website: https://www.atopiyo.com/en/
